Garabet Yeretssian is director of the Helmsley Charitable Trust’s Crohn’s Disease Program, which supports impactful ideas and mobilizes a global community committed to improving the lives of Crohn’s disease patients while pursuing a cure. Prior to joining Helmsley, Yeretssian was an assistant professor in the Immunology and Tisch Cancer Institutes at the Icahn School of Medicine at Mount Sinai, where he led a research team investigating the implication of innate immune and cell death mechanisms in inflammatory bowel diseases, Crohn’s disease, colorectal cancer, and other gastrointestinal disorders. Previously, he was a postdoctoral fellow and later on an associate researcher at McGill University, studying host-microbe interactions at gut mucosal surfaces.
Previously
If the idea of fecal transplants seems momentarily disquieting, consider that they achieve a 90 percent cure rate for the devastating intestinal infection known as C. diff whe...
Fueled by a sense of mission and the recognition that neither government nor the private sector alone can set society on an optimal course, foundations play a unique role in p...
Inflammation in the gut has been identified as one of the culprits in a long list of chronic illnesses, including colorectal cancer, diabetes, rheumatoid arthritis, and Crohn’...